| 霍奇金淋巴瘤治疗新进展：第55届美国血液学会年会报道 |
| |
| 引用本文： | 吴梦,朱军. 霍奇金淋巴瘤治疗新进展：第55届美国血液学会年会报道[J]. 白血病．淋巴瘤, 2014, 23(1): 5-8 |
| |
| 作者姓名： | 吴梦 朱军 |
| |
| 作者单位： | 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤科 |
| |
| 摘 要： | 2013年第55届美国血液学会（ASH）年会针对霍奇金淋巴瘤（HL）进行了专题报道,包含早期放化疗治疗选择、靶向治疗进展及结节性淋巴细胞为主型的HL治疗现状等内容.文章强调HL的治疗需结合病程特点及评效结果制定个体化治疗计划,以兼顾近期有效率及远期生存率.靶向治疗的有效性以及结节性淋巴细胞为主型HL治疗策略尚需进一步临床试验数据支持.
|
| 关 键 词： | 霍奇金淋巴瘤 美国血液学会年会 |
Novel therapy for Hodgkin lymphoma: reports in the 55th ASH annual meeting |
| |
| Wu MengKey Laboratory of Carcinogenesis and Translational ResearchMinistry of Education. Novel therapy for Hodgkin lymphoma: reports in the 55th ASH annual meeting[J]. Journal of Leukemia & Lymphoma, 2014, 23(1): 5-8 |
| |
| Authors: | Wu MengKey Laboratory of Carcinogenesis and Translational ResearchMinistry of Education |
| |
| Affiliation: | Wu Meng(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital ＆ Institute, Beijing 100142, China) Zhu Jun(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital ＆ Institute, Beijing 100142, China) |
| |
| Abstract: | The 55th ASH annual meeting published a special report about Hodgkin lymphoma, which mainly contains management of early-stage Hodgkin lymphoma, novel targeted therapy and the optimal treatment of lymphocyte-predominant Hodgkin lymphoma. The therapy of Hodgkin lymphoma should be individualized, in order to improve both PFS and OS. More clinical trials should be designed on the target therapy and the treatment strategy of nodular lymphocyte-predominant Hodgkin lymphoma. |
| |
| Keywords: | Hodgkin lymphoma ASH annual meeting |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《白血病．淋巴瘤》浏览原始摘要信息 |
|
点击此处可从《白血病．淋巴瘤》下载免费的PDF全文 |
